Preclinical safety and efficacy of cannabidivarin for early life seizures
Sign Up to like & getrecommendations! Published in 2019 at "Neuropharmacology"
DOI: 10.1016/j.neuropharm.2019.01.002
Abstract: ABSTRACT A significant proportion of neonatal and childhood seizures are poorly controlled by existing anti‐seizure drugs (ASDs), likely due to prominent differences in ionic homeostasis and network connectivity between the immature and mature brain. In… read more here.
Keywords: safety; early life; cbdv; efficacy ... See more keywords
Cannabidivarin alleviates neuroinflammation by targeting TLR4 co-receptor MD2 and improves morphine-mediated analgesia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.929222
Abstract: Toll-like receptor 4 (TLR4) is a pattern-recognition receptor (PRR) that regulates the activation of immune cells, which is a target for treating inflammation. In this study, Cannabidivarin (CBDV), an active component of Cannabis, was identified… read more here.
Keywords: md2; tlr4; cannabidivarin alleviates; tlr4 receptor ... See more keywords